Literature DB >> 29960275

Novel Immunoassay for Complement Activation by PF4/Heparin Complexes.

Sanjay Khandelwal1, Alexandra M Johnson1, Jian Liu2, David Keire3, Cynthia Sommers3, Joann Ravi1, Grace M Lee1, John D Lambris4, Edimara S Reis4, Gowthami M Arepally1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29960275      PMCID： PMC6288012          DOI： 10.1055/s-0038-1660858

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  10 in total

1.  Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.

Authors:  G M Arepally; S Kamei; K S Park; K Kamei; Z Q Li; W Liu; D L Siegel; W Kisiel; D B Cines; M Poncz
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

2.  The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21).

Authors:  Sanjay Khandelwal; Grace M Lee; C Garren Hester; Mortimer Poncz; Steven E McKenzie; Bruce S Sachais; Lubica Rauova; Garnett Kelsoe; Douglas B Cines; Michael Frank; Gowthami M Arepally
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113

3.  Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies.

Authors:  Grace M Lee; Manali Joglekar; Maragatha Kuchibhatla; Sanjay Khandelwal; Rui Qi; Lubica Rauova; Gowthami M Arepally
Journal:  Blood Adv       Date:  2017-04-18

4.  Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder.

Authors:  Theodore E Warkentin; Paul A Basciano; Jared Knopman; Richard A Bernstein
Journal:  Blood       Date:  2014-03-27       Impact factor: 22.113

5.  Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery.

Authors:  T L Bauer; G Arepally; B A Konkle; B Mestichelli; S S Shapiro; D B Cines; M Poncz; S McNulty; J Amiral; W W Hauck; R N Edie; J D Mannion
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

6.  Complement activation by interaction of polyanions and polycations.

Authors:  B A Fiedel; R Rent; R Myhrman; H Gewurz
Journal:  Immunology       Date:  1976-02       Impact factor: 7.397

7.  Heparin modifies the immunogenicity of positively charged proteins.

Authors:  Shalini L Chudasama; Benjamin Espinasse; Fred Hwang; Rui Qi; Manali Joglekar; Galyna Afonina; Mark R Wiesner; Ian J Welsby; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2010-09-17       Impact factor: 22.113

8.  Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.

Authors:  Yuzhou Zhang; Dingwu Shao; Daniel Ricklin; Brieanna M Hilkin; Carla M Nester; John D Lambris; Richard J H Smith
Journal:  Immunobiology       Date:  2015-05-05       Impact factor: 3.144

9.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

10.  Authentication of animal origin of heparin and low molecular weight heparin including ovine, porcine and bovine species using 1D NMR spectroscopy and chemometric tools.

Authors:  Yulia B Monakhova; Bernd W K Diehl; Jawed Fareed
Journal:  J Pharm Biomed Anal       Date:  2017-10-27       Impact factor: 3.935
  10 in total
  6 in total

1.  C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates.

Authors:  Jean Kwun; Stuart J Knechtle; Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Miriam Manook; Janghoon Yoon; Mingqing Song; John S Yi; Sanjay Khandelwal; Gowthami M Arepally; Alton B Farris; Edimara S Reis; John D Lambris
Journal:  Nat Commun       Date:  2021-09-15       Impact factor: 17.694

Review 2.  Is complement the culprit behind COVID-19 vaccine-related adverse reactions?

Authors:  Dimitrios C Mastellos; Panagiotis Skendros; John D Lambris
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

3.  Antimicrobial Peptide Arenicin-1 Derivative Ar-1-(C/A) as Complement System Modulator.

Authors:  Ilia A Krenev; Ekaterina S Umnyakova; Igor E Eliseev; Yaroslav A Dubrovskii; Nikolay P Gorbunov; Vladislav A Pozolotin; Alexei S Komlev; Pavel V Panteleev; Sergey V Balandin; Tatiana V Ovchinnikova; Olga V Shamova; Mikhail N Berlov
Journal:  Mar Drugs       Date:  2020-12-10       Impact factor: 5.118

4.  Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.

Authors:  Christina Lamers; Xiaoguang Xue; Martin Smieško; Henri van Son; Bea Wagner; Nadja Berger; Georgia Sfyroera; Piet Gros; John D Lambris; Daniel Ricklin
Journal:  Nat Commun       Date:  2022-09-20       Impact factor: 17.694

5.  Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes.

Authors:  Sanjay Khandelwal; Ayiesha Barnes; Lubica Rauova; Amrita Sarkar; Ann H Rux; Serge V Yarovoi; S Sergei Zaitsev; John D Lambris; Sooho S Myoung; Alexandra Johnson; Grace M Lee; Madelaine Duarte; Mortimer Poncz; Gowthami M Arepally; Douglas B Cines
Journal:  Blood       Date:  2021-11-25       Impact factor: 22.113

6.  Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.

Authors:  Sanjay Khandelwal; Joann Ravi; Lubica Rauova; Alexandra Johnson; Grace M Lee; Jennifer B Gilner; Sreenivasulu Gunti; Abner L Notkins; Maragatha Kuchibhatla; Michael Frank; Mortimer Poncz; Douglas B Cines; Gowthami M Arepally
Journal:  Blood       Date:  2018-10-11       Impact factor: 25.476
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.